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Abstract: Background: Severe COVID-19 infection often leads to impairments requiring pulmonary
rehabilitation (PR) following the acute phase. Little is known about the efficacy of PR in these
patients. We therefore compared post-COVID-19 patients (PG) referred to PR patients with other
lung diseases (LG). Methods: 99 PG were admitted to PR. In a prospective design, the results of
PG were collected and compared to the results of LG of 2019 (n = 419) according to Functional
Independence Measurement (FIM), Cumulative Illness Rating Scale (CIRS), 6-min walk test (6-MWT),
duration of PR, and Feeling Thermometer (FT). Results: According to age, sex, and CIRS, both groups
showed no significant differences. The improvements in the 6-MWT in the pre to post comparison
were on average 180 (±101) meters for PG and 102 (±89) meters for LG (p < 0.001). FT showed a
significant enhancement for PG of 21 (±14) points and for LG of 17 (±16) points (p < 0.039), while
FIM significantly increased by 11 (±10) points in PG and 7 (±8) points in LG (p < 0.001). Conclusions:
Comprehensive PR in PG is very effective according to the results in FIM, 6-MWT and FT. Therefore,
we recommend PR following severe post-COVID-19 infections.
Keywords: COVID-19; pulmonary rehabilitation; FIM; 6-MWT; FT; CIRS
1. Introduction
The COVID-19 pandemic was first identified in Wuhan, Hubei Province, China, in
December 2019 [1]. Patients with COVID-19 typically present with symptoms of fever,
cough, and dyspnea [2–4]. Less common symptoms include myalgias/fatigue, rhinorrhea,
sore throat, headache, and diarrhea [2]. Bilateral ground glass opacities, as well as bilateral
multiple lobular and subsegmental areas of consolidation, are described as typical imaging
findings [5]. Complications include respiratory failure, non-pulmonary complications
such as acute myocardial injury, renal failure or thromboembolic events, septic shock, and
multiple organ failure in severe cases. Therefore, a large number of patients with severe
COVID-19 suffer from functional physical and partly psychological limitations [6,7].
A significant number of patients with COVID-19 admitted to rehabilitation have spent
time in the intensive care unit (ICU) and have symptoms common to other ICU patients,
including dyspnea, anxiety, depression, prolonged pain, impaired physical function and
poor quality of life [7,8]. Although the lung is the primary target of coronavirus infection,
clinical signs of central (i.e., dizziness, headache, and/or impaired consciousness) and/or
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peripheral nervous system (i.e., taste and/or smell impairment) involvement have been
reported, especially in patients requiring mechanical ventilation [9].
Based on the above-described functional deficits, many patients need pulmonary
rehabilitation (PR) following the acute phase. For these patients, a step-by-step concept of
a comprehensive multimodal and interdisciplinary PR is needed, differentiated according
to the extent of the impairment caused by the infection, the activity restrictions, and the
participation disorders. For most patients, an inpatient setting is necessary due to the
complexity and degree of the limitations [10]. However, inpatient PR during the COVID-19
pandemic can only occur under considerable restrictions (significantly reduced number
of patients and therapies, personnel–intensive care, high hygienic expenses), especially
if isolation is still required. In a previous study, we showed that isolation not only leads
to reduction of therapies but also has a negative impact on the outcome of a pulmonary
rehabilitation program [11].
The course of the disease can be complicated by the necessity of retransfer to an acute
clinic due to a renewed deterioration. Many patients admitted to PR still have residual
infiltrates and/or possibly permanent fibrosis/interstitial affections causing limitations
in gas exchange [12]. A close monitoring of the course containing functional diagnostics
and imaging of these changes is required, especially with regard to the resulting functional
restrictions [13,14].
The goals of PR in COVID-19 are very similar to those of PR in other pulmonary
diseases, i.e., improvements in persisting functional physical limitations, performance,
endurance, and disabilities resulting from further organ complications. According to
the psychological aspects, professional support in coping with the illness after an often
long and complicated intensive stay is necessary [15]. Finally, restoration of the ability to
perform at work and in everyday social life represents the participation-oriented goals.
However, little is known regarding to what extent these goals of PR can be achieved in
post-COVID-19 patients, particularly in comparison to patients with pulmonary diseases
usually referred to PR. The first experiences with PR in post-COVID-19 patients indicated
that improvements were significant according to physical performance and subjective
health status regardless of previous ventilation [12].
We hypothesized that post-COVID-19 patients would benefit from PR as much as
other patients with lung diseases. Thus, we compared the PR results, e.g., 6-min walk test
(6-MWT), Feeling Thermometer (FT), and Functional Independence Measurement (FIM),
of all post-COVID-19 patients to the outcome of patients with lung diseases referred to PR
in 2019.
2. Materials and Methods
2.1. Participants and Procedures
All patients were referred for PR to the Zurich RehaCenter Klinik Wald, Switzerland
after hospitalization between March and December 2020 following acute care phase of a
COVID-19 infection. The data of these patients were prospectively analyzed according
to performance and outcome during rehabilitation and were compared to the cohort of
rehabilitation participants with different pulmonary diseases of the year 2019. Data of
this patient group (lung diseases (LG)) were retrospectively analyzed to describe potential
differences, performance, and outcome during PR of patients after severe COVID-19. In
total, 92% of the patients of the control group participated in the PR program following
severe exacerbation of their pulmonary disease requiring hospitalization. We used the
German version of the program RehaTISTM by Softsolution, International AG, 15830 Lahti,
Finland to record and control the individual rehabilitation process of each participant,
including all therapies and procedures. The patient data and results of the assessments
were stored and taken for evaluation out of the clinic information system PhoenixTM,
CompuGroup Medical AG, 3007 Bern, Switzerland.
Post-COVID-19 patients were eligible for PR as soon as they were hemodynamically
stable without the need of catecholamine or invasive ventilation and continuous monitoring.
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In the initial phase of the corona crisis in Switzerland, patients were admitted after being
asymptomatic for 2 days and 10 days after onset of infection. Later on, patients were
additionally required to have at least one negative swab before transfer, while between
June and December, the swab strategy was dropped again, and the initial regulations were
valid again. All patients gave written informed consent, and the local ethics committee
approved the study protocol (BASEC-No 2020-01061). This study is registered at the
German Clinical Trials Register (DRKS00024613).
Within two days after admission for rehabilitation, all patients from the COVID-19
cohort and PR cohort of 2019 were assessed with questionnaires, such as Chronic Respira-
tory Disease Questionnaire (CRQ), Hospital Anxiety and Depression Scale (HADS), and
Cumulative Illness Rating scale (CIRS) and Functional Independence Measure (FIM). To
measure changes during rehabilitation, 6-min walk test (6-MWT) and Feeling Thermome-
ter (FT) were performed on admission and before discharge. All patients were deemed
cognitively able to provide valid responses to the questionnaires by treating physicians.
Comorbidities, pulmonary function testing (PFT), and laboratory values including blood
gas analysis were assessed.
2.2. Pulmonary Rehabilitation
The standardized inpatient PR program had a duration of 3 weeks, including a total
of 25–30 therapy sessions on 5–6 weekdays. The multimodal program mainly consisted of
an individualized endurance exercise and strength training and was carried out according
to a protocol adapted to the severity of the disease and functional physical limitations.
Monday to Friday, patients participated in a maximum of 4 exercise sessions per day. On
Saturday, one exercise session was offered, and Sunday was exercise-free. Exercise therapy
consisted of endurance training (cycling and treadmill), gymnastics (3 levels), in- and
outdoor walking (3 levels), and strength training.
For cycling exercise, a low-intensity interval program was chosen if the initial 6-MWT
distance was <200 m. In this cohort, a walking distance of <200 m according to the initial
6-MWT was found in 58 patients. The duration of the higher and lower intensity intervals
was set to 30–60 (55–70% of maximum heart rate) and 60 s, respectively. The rate of
perceived exertion (RPE) measured by the adapted Borg Scale (1–10) was used to define
and adapt exercise intensity with a goal of Borg 4–6 (dyspnea) during exercise [16–18].
Since most patients were very weak on PR admission, exercise started at very low intensity
and increased continuously according to the patients’ tolerance. RPE was assessed after
each exercise session. Duration of cycling was titrated individually starting at 5–10 min
at entry and increasing over time up to 30–35 min at discharge. Exercise duration was
usually increased first, with the goal to reach 20 min. After that, intensity was increased
as well. All patients were monitored using pulse oximetry during their exercise. Criteria
for stopping or reducing exercise intensity were an oxygen saturation (SpO2) < 88% and
dyspnea symptoms (Borg ≥ 6). When a drop in SpO2 was observed, oxygen was added
with a maximum of 6–8 L per minute via nasal cannula to keep the SpO2 > 90%. More
than half of PG patients (n = 58) had an initial 6-MWT distance < 200 m, which required
an individual adaptation of training. Partially bedridden patients started with in-bed
cycling and MOTO-Med® (RECK-Technik GmbH & Co. KG Medizintechnik, Reckstraße
1–5, D-88422 Betzenweiler, Germany). This was followed by first walking attempts with
walking aids until first cycling interval training was possible. For fitter patients (6-MWT
distance > 200 m), endurance training was carried out either on the treadmill or cycle
ergometer. The speed of treadmill training was calculated based on the result of the 6-MWT
(80% of 6-MWT pace; 6-MWT distance × 0.008 = exercise speed in km/h) but was also
symptom-limited (Borg ≥ 6).
Outdoor walking was offered at different levels, with level 1 at a slow pace with little
incline of the terrain and level 3 at a faster pace with frequent inclines. To decide which
level of gymnastics or outdoor walking suited a patient, the result of the 6MWD was used
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(gymnastics: 6-MWT < 200 m = level 1, >400 = level 3) or an individual outdoor test walk
was performed.
Gymnastics was offered in three levels of intensity. Whereas exercises in gymnastics
level 1 took place mostly in a sitting position with several breaks between exercises, level 3
consisted of exercise in a standing position or walking with only very few or no breaks at
all between exercises. Gymnastics consisted of a mixture of exercises to improve endurance,
strength, coordination, range of motion, and balance.
A physio- or sports therapist instructed strength exercise 3–4 times per week indi-
vidually according to recent American Thoracic Society/European Respiratory Society
recommendations [17]. The modified Borg Scale was used to define exercise intensity with
the goal of Borg 4–5. Usually, 3 series of 8–12 repetitions per exercise and 3–5 exercises
for large muscle groups were chosen. In addition, patients received inspiratory muscle
training and relaxation (progressive muscle relaxation).
Respiratory physiotherapy consisted of teaching breath control (pursed lip breathing,
secretion mobilization, and diaphragmatic breathing), energy saving techniques, and
controlled coughing exercises.
Twice a week (1 h each), all patients participated in educational sessions, including self-
management, coping skills, self-medication, management of infections and exacerbations,
dyspnea, use of oxygen, and nutrition interventions. If needed, patients took part in a
structured smoking cessation program, received psychosocial support or diabetes advice.
Table 1 provides an overview of the different therapies and their respective durations.
Table 1. Available exercise frequency and minutes of therapies.





Outdoor walking 2–3 45
Strength training 3–4 30
Relaxation 2 45
Respiratory therapy 3 30
2.3. Hygiene Concept during Rehabilitation
For the treatment and management of COVID-19 patients, the recommendations of the
Swiss Noso (Swiss National Institute of Infection-Prevention) and the Health Department of
the Kanton Zurich were applied. The hygiene concept has been published recently [11,12].
An assessment of the hygienic risk was made for the individual patient. If isolation was
indicated, the patients were transferred to the isolation ward where they were supervised
in a single room. The frequency of these treatments was adapted to the individual and
diagnosed limitations and needs of the patients. Due to the risk of infection, a ban on visits
by relatives was implemented by the Health Department of the Kanton of Zurich for both
the first and the second wave. This ban on visits was very stressful for the patients and in
some cases also led to shortened stays in rehabilitation or even to direct discharge to their
homes without rehabilitation.
2.4. Exercise Capacity
Exercise capacity was measured at hospital admission and discharge using the 6-min
walk test (6-MWT), performed once at the beginning and once at the end of the PR program
after 20 days, according to the guidelines of the American Thoracic Society and carried out
by experienced, well-instructed examiners [19]. A change of 14.0 to 30.5 m was found to be
clinically important across multiple patient groups [20]. Recently, for patients surviving
acute respiratory failure or acute respiratory distress syndrome, a minimally important
difference (MID) of 20 to 30 m was determined [21]. The median distance walked in the
6-MWT for healthy adults is described as 576 m for men and 494 m for women [22].
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2.5. Quality of Life
As the standardized health-related quality of life (HRQoL) measurement tool, the
German version of the Chronic Respiratory Disease Questionnaire (CRQ) was used. The
questionnaire measures eight dimensions of HRQoL and allows calculation of two sum-
mary scales of physical and mental experienced [23].
2.6. Functional Independence Measure (FIM)
The FIM is an 18-item measurement tool that explores the severity of an individual’s
physical and psychological disability, especially of rehabilitation patients. [24]. The tool
is also used to assess a change in patients’ functional status in response to rehabilitation
or medical intervention. The FIM uses the level of assistance an individual needs to
grade functional status from total independence to total assistance. As the severity of
disability changes during rehabilitation, the data generated by the FIM Instrument can
be used to track such changes and analyze the outcomes of rehabilitation. FIM change
scores associated with MID were 22 for the total FIM, motor FIM, and cognitive FIM,
respectively [25].
2.7. Hospital Anxiety and Depression Scale (HADS)
The HADS was originally designed as a short, easy-to-use, 14-item screening tool for
depression in patient status in response to rehabilitation. Both scales ranging from 0 to 21
with higher scores indicate more severe distress [26].
2.8. Cumulative Illness Rating Scale (CIRS)
We used the CIRS to assess a patient’s level of disability and as an indicator of health
status, including predicted 18-month mortality and social function [27]. The calculated
CIRS on admission is useful for predicting important hospital outcomes such as high risk
of death or long stays and to better anticipate end of life issues.
2.9. Feeling Thermometer (FT)
We used the FT to determine and compare patients’ feelings about their actual wellbe-
ing by applying a numeric rating of their feelings toward an imaginary scale in terms of
degrees, with their attitudes corresponding to temperatures. The MID is defined between 5
and 8 degrees [28].
2.10. Pulmonary Function Tests (PFT) and Blood Gas Analysis
Spirometry and Body-Plethysmography (Master Screen Body; Jaeger GmbH, Hoech-
berg, Germany) were performed once on PR discharge in accordance with recent guide-
lines [29,30]. Arterial blood gases were taken at rest under room air condition (Radiometer
ABL800, Willich, Germany) at the admission to PR [31]. Blood count, creatinine, and
C-reactive protein (CRP) were obtained from the external laboratory Medica, Medizinische
Laboratorien Dr. F. Kaeppeli AG, Zurich.
2.11. Statistics
Binary variables were presented as relative and absolute frequencies, and the Fisher’s
exact test was used for group comparison. Normally distributed continuous variables were
presented as mean with standard deviation (SD), and the t-test was used for comparison
between groups. Not normally distributed continuous variables were presented as median
with inter-quartile range (IQR), and the Mann–Whitney-U-Test was used for group compar-
ison. For time-dependent comparisons, paired t-test was calculated. Boxplots were used as
graphical presentation of the data. Linear models were calculated for multivariate analysis.
p-value < 0.05 was considered as statistically significant. All analyses were conducted
using Microsoft R Open 4.0.2, Microsoft Corporation, One Microsoft Way, Redmond, WA
98052-6399, USA.
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3. Results
Between March and December 2020, 99 post-COVID-19 patients (PG) were referred to
PR, and their results were compared to those of patients with different pulmonary diseases
referred to PR in 2019 (n = 419) (LG).
3.1. Baseline Characteristics of the Post-COVID-19 Group (PG) and the Control Group (LG)
According to age, sex distribution, duration of PR, and CIRS, no significant differences
were found between PG and LG. The results of the comparison of both groups are provided
in Table 2. The BMI was significantly higher in the PG (28.21 vs. 24.5; p < 0.001). In the LG,
COPD was the most common diagnosis (53%), followed by infectious pulmonary diseases
(13%) and lung cancer (13%).
Table 2. Comparison of the post-COVID-19 group (PG) to the lung diseases group (LG).
PG (n = 99) LG (n = 419) p
Age (mean) 67.72 (±10.23) 69.28 (±11.29) 0.207
Sex, female (%) 42 (±42.4) 213 (±50.8) 0.163
BMI kg/m2 (mean) 28.21 (±6.11) 24.50 (±6.10) <0.001
PR days (median [IQR]) 20 [18.00, 22.00] 21 [18.00, 21.00] 0.042
CIRS points (mean) 14.18 (±5.92) 14.52 (±5.6) 0.324
Notes: PG, post-COVID-Group; LG, lung diseases group; BMI, body mass index; PR, pulmonary rehabilitation;
CIRS, Cumulative Illness Rating Scale.
3.2. Comorbidities of the Post-COVID-19-Group (PG) and Complications Due to the
COVID-19 Infection
The mean duration of the acute hospital stay of the PG was 25.9 (±8.81) days, with
11.3 (±12.5) days in the ICU and 7 (±9.18) days on ventilation. In total, 65 patients (66%)
needed ICU care. On average, 2.9 comorbidities prior to the COVID-19 infection were
present for PG patients with hypertension as the most prevalent comorbidity (54%). Table 3
provides the comorbidities of the PG.
Table 3. Comorbidities of post-COVID-19 patients prior to COVID-19 infection.
Comorbidities Prior COVID-19
(n = 99) n (%)
Hypertension 54 (54)
Smokers or Ex-Smokers 27 (27)
Adiposities 25 (25)
Musculoskeletal disease 25 (25)
Dyslipidemia 20 (20.2)
Neurological disease 20 (20)
Chronic renal failure 19 (19)
Coronary artery disease 18 (18.2)
Malignancy 15 (15)
COPD 11 (11)
Cerebrovascular insufficiency 9 (9)
Atrial Fibrillation 8 (8.1)
Diabetes 8 (8)
Obstructive sleep apnea 7 (7)
Chronic heart failure 6 (6)
Venous thromboembolism 5 (5)
Interstitial lung disease 5 (5)
Liver disease 5 (5)
Notes: ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.
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Table 4 provides the complications due to the COVID-19 infection and the new diag-
nosis made during the hospital stay or during the rehabilitation indicating that the patients
experienced on average 2.7 complications or new diagnosis.
Table 4. Complications due to COVID-19 infection or new diagnosis made during inpatient stay.
Complications or New Diagnosis n (%)
Sepsis 37 (37)
Delirium 36 (35)
ARDS severe 27 (27)
ICU acquired weakness 24 (24)
Anemia 24 (24)
Electrolyte disturbance 18 (18)
Acute renal failure 14 (14)
Atrial Fibrillation 13 (13)
Myocarditis 12 (12)
Hepatitis 12 (12)
Venous Thromboembolism 11 (11)
Bacterial superinfection 11 (11)
Diabetes 8 (8)
Arterial Hypertension 6 (6)
Acute Heart failure 4 (2)
ARDS mild 4 (4)
COPD 1 (1)
Coronary Artery Disease 1 (1)
Pulmonal Artery Disease 1 (1)
Notes: ARDS, acute respiratory distress syndrome; ICU, intensive care unit; COPD, chronic obstructive pul-
monary disease.
3.3. Assessments on Admission or Discharge to PR of the Post-COVID-19 Group
Table 5 shows the results of the assessments and the laboratory parameters of the PG
at admission to PR as well as the results of the Pulmonary Function Test. Chest X-rays
at discharge from PR showed significant infiltrates in 69 (70%) of the PG. Oxygen supply
at acute hospital discharge was necessary in 52 patients (53%), while oxygen supply at
discharge from PR was needed in 25 patients (25%). Length of stay was 45.9 days (25.9 days
in acute hospital and 20 days at PR) for the PG. Pulmonary Function Tests were available
for 69 patients. A total of 12 patients (17%) had mild (n = 12; 17%), 28 patients (41%)
moderate, and 11 patients severe (41%) restrictive ventilation pattern at the last third of PR.
No restriction was found in 18 patients (26%). Diffusion capacity in the PG was found to
be limited mild in 14 (20%), moderate in 28 (41%), and severe in 18 (26%) patients, while 9
(13%) patients had normal diffusion capacity.
3.4. Results of Pulmonary Rehabilitation in the PG and LG
Figures 1–3 show the results of the assessments at admission and discharge for both
groups. PG and LG showed significant improvements during PR according to FIM, 6-
MWT, and FT in the intragroup comparison. Improvements in the intergroup comparison
were higher in the PG compared to the LG. The increase in the 6-MWT in the pre to
post comparison were on average 180 (±101) meters for PG and 102 (±89) meters for LG
(p < 0.001). FT showed a significant enhancement for PG of 21 (±14) points and for LG of
17 (±16) points (p < 0.039), while FIM significantly increased with 11 (±10) points in PG
and 7 (±8) points in LG (p < 0.001).
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Table 5. Results of the assessments at admission to PR of the post-COVID-19 Group (PG).
Mean SD
Assessments on admission to PR (n = 99)
CIRS; points 14.2 5.8
HADS A; points 5.58 3.87
HADS D; points 5.52 3.09
FIM total; points 100 15.1
FIM social; points 29 4,65
FIM motoric; points 71.4 12.3
CRQ; points 4.66 0.93
Laboratory parameters on admission to PR
PaO2 (kPa) (n = 72) 9.22 1.85
PaCO2 (kPa) (n = 72) 4.6 0.68
SpO2% (n = 99) 93.6 3
C-Reactive Protein (mg/dL) (n = 88) 151 134
Ferritin (mg/L) (n = 55) 1190 1170
Hemoglobin (mg/L) (n = 99) 99.8 24.1
Creatinin (mg/L) (n = 99) 128 122
Pulmonary function test at discharge PR (n = 69)
FEV1 % pred. 74.9 38.94
FVC % pred. 74.1 37.6
FEV1 % FVC 85.2 25.6
DLCO % pred. 61 38.56
Notes: CIRS, Cumulative Illness Rating Scale; HADS A, Hospital Anxiety and Depression Scale Anxiety; HADS D,
Hospital Anxiety and Depression Scale Depression; FIM, Functional Independence Measurement; CRQ, Chronic
Respiratory Questionnaire; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DLCO,
lung diffusion capacity.
Figure 1. 6-min walk test of post-COVID-19 Group and lung diseases group.
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Figure 2. Feeling thermometer of post-COVID-19 group and lung diseases group. ns: no significative.
Figure 3. Functional Independence Measurement of post-COVID-19 group and lung diseases group.
ns: no significative.
Results of inter- and intragroup comparisons of FIM, 6-MWT, and FT on admission
and discharge to PR are displayed in Table 6, showing significant improvements for all
parameters in both groups in the intragroup comparison. While there were no significant
differences found at discharge to PR for FT and FIM between both groups, the 6-MWT
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distance was significantly smaller for the PG. The increase for all parameters during PR
was significantly higher for the PG in the intergroup comparison.
Table 6. Inter- and intragroup comparisons of FT, FIM and 6-MWT on admission and discharge
to PR.
LG PG Intergroup





































Notes: FIM, Functional Independence Measurement; 6-MWT, 6-min walk test; FT, feeling thermometer.
3.5. Multivariate Analysis of the Results
In order to prove results really depend on the group affiliation, a linear model was
performed with the ∆ of FT, FIM, and 6-MWT as the dependent variable. Table 7 provides a
multivariate analysis showing that the LG group affiliation has significant negative impact
on the change in 6-MWT, FT, and FIM regardless of age, BMI, and sex.
Table 7. Multivariate analysis with the ∆ of the FT, the FIM and the 6-MWT as the dependent variable.
∆ FT ∆ FIM ∆ 6-MWT
Beta [95% CI] p Beta [95% CI] p Beta [95% CI] p
(Intercept) 20.09 [6.32–33.87] 0.004 9.49 [2.43–16.55] 0.009 237.47 [172.84–302.09] <0.001
No Covid (LG) −4.37 [−8.23–−0.52] 0.026 −3.62 [−5.69–−1.56] 0.001 −81.03 [−101.78–−60.27] <0.001
Age 0.06 [−0.10–0.21] 0.477 0.00 [−0.08–0.07] 0.933 −0.32 [−1.04–0.39] 0.374
Sex, female 0.00 [−3.36–3.36] 0.999 −1.40 [−3.10–0.30] 0.105 −11.55 [−27.38–4.28] 0.153
BMI −0.09 [−0.37–0.19] 0.526 0.08 [−0.05–0.22] 0.232 −1.06 [−2.36–0.24] 0.108
Notes: FT, Feeling Thermometer; FIM, Functional Independence Measurement; 6-MWT, Six-Minute Walk Test; BMI, body mass index.
4. Discussion
To the best of our knowledge, this is the first study comparing the results of PR of a
larger group of severely impaired Post-COVID-19 patients to individuals usually referred
to PR. Our results demonstrate that improvements during PR were significantly higher
for the PG. This was not only true for the physical performance measured with FIM and
6-MWT but also for the actual wellbeing of the patients indicated by the results of the FT.
It is known that up to one third of COVID-19 patients developed severe pulmonary
complications and acute respiratory distress syndrome (ARDS), leading to persistent
impairments in pulmonary function and physical performance [2]. Indeed, the severity
of impairments was more pronounced in patients with severe and critical COVID-19
courses [32]. Previously, we showed that patients with acute deteriorations of pulmonary
function do benefit from PR [33]. However, little is known about the extent to which
post-COVID-19 patients benefit from PR. The limitations in physical capacity according to
the results of the initial 6-MWT of post-COVID-19 patients exceed the limitations observed
in patients usually participating in PR. Nevertheless, post-COVID-19 patients did benefit to
a greater extent from PR than LG. Indeed, our multivariate analysis clearly demonstrated
that COVID-19 itself had a strong impact on changes in FT, FIM, and 6-MWT.
Despite the pronounced limitations, we suspect the cause of the significantly higher
improvements to be the greater recovery potential of post-COVID patients compared with
chronically ill patients, many of whom had long-standing pulmonary disease. Apparently,
the pre-existing and acquired comorbidities in the context of COVID-19 infection were
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comparable to the lung diseases group, yet the potential for improvement was higher in
the PG. We suspect that the acquired physical and psychological limitations in the PG
were predominantly at least partially reversible, which was obviously not the case in the
LG. However, our results are in line with a recent publication reporting significant im-
provements in performance status and lung function of COVID-19 patients by a structured
multidisciplinary rehabilitation program [34].
Despite the significant improvements in our COVID-19 cohort, chest X-rays, spirome-
try, body plethysmography, and lung diffusion capacity (DLCO) were still impaired even
at the end of PR. These results are in line with the study of Puchner et al. showing that
57% of all COVID-19 patients had pathological FEV1, FVC, and/or TLC < 80%, and 83%
of all study participants still had a reduction of the DLCO at the end of the rehabilitation
program [34]. Compared to Puchner et al., our COVID-19 patients showed significantly
higher physical limitations in 6-MWT on PR admission; however, the absolute improve-
ments during PR were identical. The observed differences in 6-MWT cannot be explained
by impaired lung function alone since available data of lung function of both studies
are comparable.
The initially very strongly elevated CRP values of PG patients indicate a still present
inflammatory load associated with disease severity and can partly explain patients’ limita-
tions. In this context, it is of note that lengths of stay in rehabilitation of COVID-19 patients
were comparable to those of normal PR patients, despite persisting limitations. Several
aspects can be taken into account for identical PR duration. One reason is the long absence
from the home environment. On average, patients were away from home for more than 45
days, which many patients reported to be enormously stressful. In addition, a ban on visits
to the clinic had to be imposed due to the pandemic, which meant that communication
with relatives was only possible via phone calls.
Although several patients still showed significant limitations before discharge, no
patient from our cohort had to be referred to an institution following PR. After participation
in PR, further care of the patients was possible in the home environment with the support
of walking aids, home care, the help of relatives or oxygen supplementation. These results
are in contrast to the findings of Roberts et al. showing that physical function deficits
in COVID-19 patients were associated with an increased odds ratio of discharge to an
institution from acute care hospitals [7]. In Switzerland, patients with severe COVID-
19 infection and persistent significant functional deficits were given the option to be
transferred to an inpatient rehabilitation program for post-acute treatment. Fortunately, the
costs for inpatient rehabilitation are covered by the Swiss health system. For this reason,
PR in the post-acute phase of severe COVID-19 infection represents an important link in
the care chain.
Study Limitations
We have to acknowledge that the present study has some limitations. First, due to
the observational design of the study, we cannot report on the causality of the observed
findings. COVID-19 specific findings cannot be claimed without an appropriate COVID-
19 control group not referred to PR. The comparison group used in this study is only
conditionally suitable to make an adequate comparison. Due to the retrospective collection
of data and the resulting missing data of the control group, direct comparison regarding,
e.g., PFT, HADS, CRQ or comorbidities has not been possible. Second, no statement
can be made about the impact of specific treatment measures since this study was rather
focused on the overall effects of the multidisciplinary treatment plan. Thus, we cannot
differentiate the influencing value of specific treatment sessions on the overall outcome of
the rehabilitation plan. Finally, this study only provides data for the immediate PR effect;
long-term results cannot be derived from this. Long-term monitoring of further PR needs,
reporting of quality of life, and long-term benefits of rehabilitation must be provided by
future studies.
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5. Conclusions
Our study provides evidence that post-acute comprehensive pulmonary rehabilitation
is associated with significant clinical and functional improvements in individuals who
suffered from severe COVID-19 and underlines the importance of post-acute rehabilitation
for COVID-19 recovery. Consequently, healthcare facilities should develop and imple-
ment plans for providing multidisciplinary rehabilitation treatments in various settings
to recover functioning and prevent the development of long-term consequences of the
COVID-19 disease.
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